ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
Financial Results:
ERIS Lifesciences Ltd reported Revenues for Q2FY24 of ₹505.00 Crores up from ₹461.00 Crore year on year, a rise of 9.54%.
Total Expenses for Q2FY24 of ₹382.00 Crores up from ₹345.00 Crores year on year, a rise of 10.72%.
Consolidated Net Profit of ₹122.00 Crores up 2.52% from ₹119.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.07, up 2.49% from ₹8.85 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.